PATENT CLAIM ANALYSIS

Application Number: 16129618
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "133100"]

Abstract:
The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Claim (Index 71):
The method of  claim 64 , wherein the transthyretin-mediated amyloidosis is associated with a condition selected from any of cardiomyopathy or hypertrophy, familial amyloid polyneuropathy, central nervous system selective amyloidosis (CNSA), senile systemic amyloidosis, senile cardiac amyloidosis, spinal stenosis, osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, age related macular degeneration, and a ligament or tendon disorder.

Metadata:
- Claim Count in Document: 273.0
- Percentile: 97.0
- Lexical Diversity: 1.64103
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15201423', '15201416', '15201429', '15861600', '15199236']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8644512335207953
- 35 USC 102 Novelty (BERT): 0.6994014679717602
- Combined Prediction Score: 0.8479462569658918
- Mean Citation Score: 697.8904719999997
- Max Citation Score: 812.8804
- Similarity Product: 708.6812015491963

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test